Breaking News Instant updates and real-time market news.

2022-08-08 10:11:09 AIRI Air Industries / + 10:11 08/08/22 08/08 10:11 08/08/22 10:11	Air Industries reports Q2 revenue $14M vs. $15.5M last year Lou Melluzzo, CEO of Air Industries said, "The Company continued to make progress in the second quarter of 2022 - a challenging period during which, like most manufacturing businesses, we faced significant supply chain disruptions affecting the availability of raw materials. Nevertheless, comparing our 2022 second quarter performance to this year's first quarter, which reflected a similar operating environment, net sales were up 16%, consolidated gross profit was up nearly 17%, and operating income rose nearly 20%. The raw material delays and delays in outside processing, regrettably, impeded the production of some customer orders, which largely contributed to the decrease in sales compared with the year-ago quarter and six month periods. That said, the recent periods demonstrate the advantages of Air Industries' diverse mix of stable aircraft product platforms and customers. While sales declined overall for the first half of 2022 versus 2021, we experienced solid increases in some platforms, namely the Northrup Grumman E2-D, and the Pratt & Whitney Geared Turbo Fan. We also saw increased volume of assemblies for the Sikorsky CH-53 helicopter. We are working diligently to address the current challenging environment. In particular, we are continuing our vertical integration strategy, which is designed to improve efficiency and shorten production times. Our in-house painting facility is up and running, and undergoing qualification, and we are establishing a function at our Sterling operation that should facilitate the assembly process for a substantial customer order The long-term prospects for our marketplace are strong. We attended the recent Farnborough Airshow, one of the key events for the aerospace industry, where the tone was generally upbeat. For example, demand remains substantial for the Lockheed Martin F-35 Joint Strike Fighter, which is the best-in-world fifth-generation fighter aircraft, and the fighter aircraft program of record for allied militaries around the globe. We are continuing to position Air Industries for enhanced performance in our growing industry through investments in vertically integrated processes and capital equipment to make us an even more valuable partner to our aerospace and defense customers, while pursuing expanded business development and sales efforts."	08 Aug

2022-08-08 10:11:09

AIRI

Air Industries

/ +

10:11

08/08/22

08/08

10:11

08/08/22

10:11

Air Industries reports Q2 revenue $14M vs. $15.5M last year

Lou Melluzzo, CEO of Air Industries said, "The Company continued to make progress in the second quarter of 2022 - a challenging period during which, like most manufacturing businesses, we faced significant supply chain disruptions affecting the availability of raw materials. Nevertheless, comparing our 2022 second quarter performance to this year's first quarter, which reflected a similar operating environment, net sales were up 16%, consolidated gross profit was up nearly 17%, and operating income rose nearly 20%. The raw material delays and delays in outside processing, regrettably, impeded the production of some customer orders, which largely contributed to the decrease in sales compared with the year-ago quarter and six month periods. That said, the recent periods demonstrate the advantages of Air Industries' diverse mix of stable aircraft product platforms and customers. While sales declined overall for the first half of 2022 versus 2021, we experienced solid increases in some platforms, namely the Northrup Grumman E2-D, and the Pratt & Whitney Geared Turbo Fan. We also saw increased volume of assemblies for the Sikorsky CH-53 helicopter. We are working diligently to address the current challenging environment. In particular, we are continuing our vertical integration strategy, which is designed to improve efficiency and shorten production times. Our in-house painting facility is up and running, and undergoing qualification, and we are establishing a function at our Sterling operation that should facilitate the assembly process for a substantial customer order The long-term prospects for our marketplace are strong. We attended the recent Farnborough Airshow, one of the key events for the aerospace industry, where the tone was generally upbeat. For example, demand remains substantial for the Lockheed Martin F-35 Joint Strike Fighter, which is the best-in-world fifth-generation fighter aircraft, and the fighter aircraft program of record for allied militaries around the globe. We are continuing to position Air Industries for enhanced performance in our growing industry through investments in vertically integrated processes and capital equipment to make us an even more valuable partner to our aerospace and defense customers, while pursuing expanded business development and sales efforts."

08
Aug

OTHER BREAKING NEWS FROM THE FLY

Downgrade	Bankinter downgraded to Underweight from Neutral at JPMorgan » 04:57 12/06/22 12/06 04:57 12/06/22 04:57 BKIMF Bankinter $6.50 / + (+0.00%) JPMorgan analyst Sofie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research BKIMF Bankinter $6.50 / + (+0.00%) 10/24/22 Berenberg Bankinter price target raised to EUR 7 from EUR 5.70 at Berenberg 10/21/22 JPMorgan Bankinter price target raised to EUR 5.60 from EUR 5.50 at JPMorgan 10/21/22 Societe Generale Bankinter price target raised to EUR 6 from EUR 5.90 at Societe Generale 10/18/22 Deutsche Bank Bankinter price target lowered to EUR 5.95 from EUR 6.05 at Deutsche Bank
Downgrade	Societe Generale downgraded to Neutral from Overweight at JPMorgan » 04:56 12/06/22 12/06 04:56 12/06/22 04:56 SCGLY Societe Generale $4.75 / -0.12 (-2.46%) JPMorgan analyst Kian… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly SCGLY Societe Generale $4.75 / -0.12 (-2.46%) 11/22/22 AllianceBernstein, Societe Generale to form cash equities JV 09/30/22 Societe Generale board picks Slawomir Krupa as next CEO 06/07/22 FIS delivers derivatives solution to Societe Generale SCGLY Societe Generale $4.75 / -0.12 (-2.46%) 11/18/22 Morgan Stanley Societe Generale downgraded to Equal Weight from Overweight at Morgan Stanley 11/07/22 JPMorgan Societe Generale price target lowered to EUR 33 from EUR 34 at JPMorgan 11/07/22 Deutsche Bank Societe Generale price target raised to EUR 37 from EUR 34 at Deutsche Bank 11/02/22 Barclays Societe Generale price target lowered to EUR 40 from EUR 42.30 at Barclays SCGLY Societe Generale $4.75 / -0.12 (-2.46%) 09/30/22 Societe Generale IB head emerging as favorite to replace CEO, Bloomberg says 07/07/22 VW selects more banks to underwrite Porsche unit IPO, Bloomberg says SCGLY Societe Generale $4.75 / -0.12 (-2.46%) 09/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Conference/Events	Fiverr management to meet with Piper Sandler » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 FVRR Fiverr $32.28 / -1.585 (-4.68%) Meeting to be held in San… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events FVRR Fiverr $32.28 / -1.585 (-4.68%) 11/09/22 Fiverr rises 11.8% 08/30/22 Fiverr announces partnership with Shutterstock 08/11/22 Fiverr partners with Selina to bring together 'Anywhere Workers' 08/04/22 Fiverr rises 13.0% FVRR Fiverr $32.28 / -1.585 (-4.68%) 11/10/22 Oppenheimer Fiverr price target lowered to $40 from $50 at Oppenheimer 11/09/22 Piper Sandler Fiverr margin expansion story 'very much on track,' says Piper Sandler 08/05/22 Needham Fiverr price target raised to $50 from $40 at Needham 08/04/22 Piper Sandler Piper Sandler applauds strategic pivot at Fiverr, keeps $50 target FVRR Fiverr $32.28 / -1.585 (-4.68%) 11/09/22 Fiverr narrows FY22 revenue $334M-$340M from $332M-$340M, consensus $336.86M 11/09/22 Fiverr sees Q4 revenue $79.8M-$85.8M, consensus $83.99M 11/09/22 Fiverr reports Q3 EPS 21c, consensus 14c 08/04/22 Fiverr cuts FY22 revenue view to $332M-$340M from $345M-$365M FVRR Fiverr $32.28 / -1.585 (-4.68%) 07/26/22 Fiverr laying off 60 employees, or 8% of workforce, Globes reports 00:00 Today Fiverr
Conference/Events	Truist leisure/lodging analyst holds an analyst/industry conference call » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 Lodging & Leisure… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Conference/Events	PlayAGS management to meet with B. Riley » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 AGS PlayAGS $5.23 / -0.13 (-2.43%) Meetings to be held in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events AGS PlayAGS $5.23 / -0.13 (-2.43%) 11/15/22 PlayAGS falls -16.6% 11/15/22 PlayAGS falls -17.0% 11/15/22 PlayAGS falls -16.5% 11/08/22 PlayAGS says 'on pace' to deliver net leverage target of less than 4.0 times AGS PlayAGS $5.23 / -0.13 (-2.43%) 08/09/22 B. Riley PlayAGS price target raised to $14 from $12 at B. Riley 08/01/22 Stifel PlayAGS price target lowered to $9 from $11 at Stifel 07/20/22 Truist PlayAGS price target lowered to $12 from $13 at Truist 07/14/22 Deutsche Bank PlayAGS price target lowered to $11 from $12 at Deutsche Bank AGS PlayAGS $5.23 / -0.13 (-2.43%) 11/08/22 PlayAGS reports Q3 EPS 1c, consensus 0c 08/08/22 PlayAGS reports Q2 EPS 4c, consensus (3c) 15 Nov AGS PlayAGS $5.23 / -0.13 (-2.43%) 08/12/22 Inspired offers to buy PlayAGS for $10 per share in cash, Reuters says 08/12/22 Inspired Entertainment bidding to buy PlayAGS, Reuters reports AGS PlayAGS $5.23 / -0.13 (-2.43%) 08/15/22 What You Missed On Wall Street On Monday 08/15/22 What You Missed On Wall Street This Morning 08/15/22 Fly Intel: Pre-market Movers 08/12/22 What You Missed On Wall Street On Friday 00:00 Today PlayAGS
Conference/Events	LKQ Corp. management to meet with Barrington » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 LKQ LKQ Corp. $53.97 / -1.07 (-1.94%) Meeting to be held in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events LKQ LKQ Corp. $53.97 / -1.07 (-1.94%) 10/27/22 LKQ Corp. raises dividend 10%, raises share repurchase plan by $1B 09/19/22 LKQ Corp. appoints Varun Laroyia as CEO, LKQ Europe, Rick Galloway as CFO LKQ LKQ Corp. $53.97 / -1.07 (-1.94%) 07/12/22 MKM Partners LKQ Corp. initiated with a Buy at MKM Partners 04/28/22 Barrington LKQ Corp. upgraded to Outperform at Barrington after beat and raise report 04/28/22 Barrington LKQ Corp. upgraded to Outperform from Market Perform at Barrington 04/11/22 Raymond James LKQ Corp. price target lowered to $59 from $62 at Raymond James LKQ LKQ Corp. $53.97 / -1.07 (-1.94%) 10/27/22 LKQ Corp. narrows FY22 adjusted EPS view to $3.85-$3.95 from $3.85-$4.05 10/27/22 LKQ Corp. reports Q3 adjusted EPS 97c, consensus 96c 07/28/22 LKQ Corp. narrows FY22 adjusted EPS view to $3.85-$4.05 from $3.80-$4.10 07/28/22 LKQ Corp. reports Q2 adjusted EPS $1.09, consensus $1.02 02/23/23 LKQ Corp. - LKQ 00:00 Today LKQ Corp.
Conference/Events	Newmark management to meet with Piper Sandler » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 NMRK Newmark $8.48 / -0.135 (-1.57%) Meetings to be held in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events NMRK Newmark $8.48 / -0.135 (-1.57%) 10/06/22 Newmark names Angie Leccese as chief marketing officer 08/15/22 Paulson buys VMware, exits DiDi in Q2 NMRK Newmark $8.48 / -0.135 (-1.57%) 10/07/22 Piper Sandler Newmark price target lowered to $10 from $12 at Piper Sandler 04/18/22 Piper Sandler Newmark downgraded to Neutral from Overweight at Piper Sandler 04/05/22 Goldman Sachs Newmark initiated with a Neutral at Goldman Sachs 03/10/22 Wolfe Research Newmark downgraded to Peer Perform from Outperform at Wolfe Research NMRK Newmark $8.48 / -0.135 (-1.57%) 10/28/22 Newmark lowers FY22 revenue view to $2.7B-$2.8B from $3.0B-$3.1B 10/28/22 Newmark reports Q3 adjusted EPS 35c, consensus 40c 07/29/22 Newmark reaffirms FY22 revenue view $3.000B-$3.100B, consensus $3.06B 07/29/22 Newmark reports Q2 GAAP EPS 26c, consensus 36c NMRK Newmark $8.48 / -0.135 (-1.57%) 10/28/22 What You Missed On Wall Street This Morning 00:00 Today Newmark 12/07/22 Newmark
Conference/Events	Matson management to meet virtually with Stephens » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 MATX Matson $61.60 / -2.89 (-4.48%) Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events MATX Matson $61.60 / -2.89 (-4.48%) 08/23/22 Matson adds 3M shares to repurchase program 08/02/22 Matson falls -9.7% 06/22/22 Matson raises quarterly dividend to 31c per share from 30c MATX Matson $61.60 / -2.89 (-4.48%) 11/17/22 Wolfe Research Wolfe reshuffles ratings in freight with five downgrades and one upgrade 11/17/22 Wolfe Research Matson upgraded to Peer Perform from Underperform at Wolfe Research 10/20/22 Stifel Matson price target lowered to $81 from $93 at Stifel 08/16/22 Wolfe Research Wolfe starts Matson at Underperform, sees 'peak EPS' in 2022 MATX Matson $61.60 / -2.89 (-4.48%) 11/02/22 Matson reports Q3 EPS $6.89, consensus $7.07 10/17/22 Matson sees Q3 EPS $6.67-$6.79, consensus $7.28 07/19/22 Matson sees Q2 $9.31-$9.42 vs $3.71 last year MATX Matson $61.60 / -2.89 (-4.48%) 10/17/22 Fly Intel: After-Hours Movers 08/16/22 What You Missed On Wall Street On Tuesday 08/16/22 What You Missed On Wall Street This Morning 08/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 00:00 Today Matson
Conference/Events	Candel Therapeutics to host a virtual research and development day » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 CADL Candel Therapeutics $1.97 / +0.08 (+4.23%) Virtual Research and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CADL Candel Therapeutics $1.97 / +0.08 (+4.23%) 11/18/22 Candel Therapeutics presents updated data from Phase 1 trial of CAN-3110 11/11/22 Candel Therapeutics presents data on CAN-2409 in combination with nivolumab 10/26/22 Candel Therapeutics partners with Penn to study novel viral immunotherapies 09/15/22 Candel Therapeutics receives orphan drug designation for CAN--2409 CADL Candel Therapeutics $1.97 / +0.08 (+4.23%) 12/02/22 H.C. Wainwright Candel Therapeutics initiated with a Buy at H.C. Wainwright 03/31/22 BMO Capital Candel Therapeutics price target lowered to $12 from $18 at BMO Capital CADL Candel Therapeutics $1.97 / +0.08 (+4.23%) 11/10/22 Candel Therapeutics reports Q EPS (30c), consensus (35c) 08/05/22 Candel Therapeutics reports 2Q EPS (14c) vs ($1.46) last year 11:00 Today Candel Therapeutics
Conference/Events	Editas Medicine to host conference call » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 EDIT Editas Medicine $9.83 / -0.425 (-4.15%) Conference call to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events EDIT Editas Medicine $9.83 / -0.425 (-4.15%) 11/17/22 Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment 11/17/22 Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial 10/18/22 Editas Medicine rises after report of talks to sell preclinical oncology assets 10/13/22 Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP EDIT Editas Medicine $9.83 / -0.425 (-4.15%) 12/05/22 Credit Suisse Editas Medicine assumed with a Neutral at Credit Suisse 11/18/22 Morgan Stanley Editas Medicine price target lowered to $8 from $10 at Morgan Stanley 11/18/22 BofA Editas' EDIT-101 setback 'not the end of the story,' says BofA 11/18/22 RBC Capital Editas Medicine price target lowered to $14 from $32 at RBC Capital EDIT Editas Medicine $9.83 / -0.425 (-4.15%) 11/02/22 Editas Medicine reports Q3 EPS (81c), consensus (86c) 08/03/22 Editas Medicine reports Q2 EPS (78c), consensus (82c) EDIT Editas Medicine $9.83 / -0.425 (-4.15%) 10/18/22 Editas in talks to sell preclinical oncology assets, Endpoints News says 07/25/22 Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says EDIT Editas Medicine $9.83 / -0.425 (-4.15%) 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/18/22 What You Missed On Wall Street On Friday 11/18/22 What You Missed On Wall Street This Morning 11/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08:00 Today Editas Medicine - EDIT

Conference/Events	Century Communities management to meet virtually with BTIG » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 CCS Century Communities $49.58 / -1.54 (-3.01%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CCS Century Communities $49.58 / -1.54 (-3.01%) 10/27/22 Century Communities falls -12.0% 10/26/22 Century Communities CFO provides FY22 outlook CCS Century Communities $49.58 / -1.54 (-3.01%) 11/29/22 BTIG Century Communities initiated with a Neutral at BTIG 11/22/22 JPMorgan Century Communities downgraded to Underweight from Overweight at JPMorgan 10/27/22 B. Riley Century Communities downgraded on margin headwinds at B. Riley 10/27/22 B. Riley Century Communities downgraded to Neutral from Buy at B. Riley CCS Century Communities $49.58 / -1.54 (-3.01%) 10/26/22 Century Communities reports Q3 EPS $4.44, consensus $4.20 07/27/22 Century Communities backs FY22 home sales revenue view $4.3B-$4.9B 07/27/22 Century Communities reports Q2 EPS $4.78, consensus $4.46 00:00 Today Century Communities
Conference/Events	iCAD management to meet virtually with BTIG » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 ICAD iCAD $1.74 / -0.08 (-4.40%) Medical Technology and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ICAD iCAD $1.74 / -0.08 (-4.40%) 11/28/22 iCAD, Google Health enter development, commercialization agreement 11/21/22 iCAD announces new research on Breast AI Suite 10/11/22 iCAD signs new agreement with Solis Mammography 08/29/22 iCAD says growing number of hospitals choos to adopt Breast AI suite ICAD iCAD $1.74 / -0.08 (-4.40%) 11/29/22 Lake Street Google Health partnership 'significant positive' for iCAD, says Lake Street 11/28/22 JMP Securities JMP views iCAD agreement with Google Health 'very favorably' 11/11/22 Lake Street iCAD price target lowered to $5 from $8 at Lake Street 09/01/22 JMP Securities iCAD price target lowered to $7 from $13 at JMP Securities ICAD iCAD $1.74 / -0.08 (-4.40%) 08/10/22 iCAD reports Q2 EPS (12c), consensus (11c) 00:00 Today iCAD
Conference/Events	DMC Global management to meet with KeyBanc » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 BOOM DMC Global $17.47 / -1.035 (-5.59%) Meetings to be held with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events BOOM DMC Global $17.47 / -1.035 (-5.59%) 09/15/22 DynaEnergetics launches IS2 Xpress upgrade 08/11/22 DMC Global announces planned retirement of CFO Kuta BOOM DMC Global $17.47 / -1.035 (-5.59%) 09/14/22 DMC Global management to meet with Roth Capital 05/03/22 Roth Capital DMC Global price target lowered to $35 from $50 at Roth Capital 12/23/21 Stifel DMC Global price target raised to $48 from $46 at Stifel BOOM DMC Global $17.47 / -1.035 (-5.59%) 11/03/22 DMC Global sees Q4 revenue $158M-$168M, consensus $160.01M 11/03/22 DMC Global reports Q3 EPS 46c, consensus 27c 08/04/22 DMC Global sees Q3 consolidated sales $155M-$163M, consensus $155.16M 08/04/22 DMC Global reports Q2 adjusted EPS 29c consensus (6c) 00:00 Today DMC Global 12/07/22 DMC Global
Conference/Events	Dynatronics management to meet virtually with Lake Street » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 DYNT Dynatronics / + Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DYNT Dynatronics / + 07/06/22 Dynatronics appoints Mike Withers as CIO, John Krier to take on CFO duties 07/06/22 Dynatronics: CEO Krier to resume CFO role, Mike Withers joins as CIO DYNT Dynatronics / + 07/27/22 Lake Street Dynatronics initiated with a Buy at Lake Street DYNT Dynatronics / + 11/10/22 Dynatronics sees 2023 revenue $45M-$48M, consensus $46.34M 11/10/22 Dynatronics reports Q1 EPS (4c), consensus (6c) 11/10/22 Dynatronics backs FY23 revenue view $45M-$48M, consensus $46.34M 11/10/22 Dynatronics reports Q1 EPS (4c), consensus (6c) DYNT Dynatronics / + 07/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 00:00 Today Dynatronics 12/07/22 Dynatronics
Conference/Events	Eagle Pharmaceuticals to host investor day » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 EGRX Eagle Pharmaceuticals $33.95 / -1.9 (-5.30%) Investor Day to be held… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events EGRX Eagle Pharmaceuticals $33.95 / -1.9 (-5.30%) 11/07/22 Eagle Pharmaceuticals sees FY22 adjusted non-GAAP R&D expense less than $40M 10/12/22 Eagle Pharmaceuticals submits IND application to FDA for CAL02 10/03/22 Eagle Pharmaceuticals, Enalare announce FDA orphan designation for ENA-001 09/27/22 Eagle and Enalare announce $50.3M contract from BARDA to develop ENA-001 EGRX Eagle Pharmaceuticals $33.95 / -1.9 (-5.30%) 12/16/21 Barclays Endo price target lowered to $5 from $7 at Barclays 12/15/21 Cantor Fitzgerald Vasopressin approval 'a key win' for Eagle Pharmaceuticals, says Cantor EGRX Eagle Pharmaceuticals $33.95 / -1.9 (-5.30%) 11/07/22 Eagle Pharmaceuticals reports Q3 adjusted EPS $1.13, consensus 91c 08/09/22 Eagle sees FY22 Adjusted non-GAAP R&D expense $46M-$50M vs $32.5M last year 08/09/22 Eagle Pharmaceuticals reports Q2 non-GAAP EPS $1.78, consensus $3.36 08:00 Today Eagle Pharmaceuticals
Conference/Events	JPMorgan transports analyst to hold an analyst/industry conference call » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 Transports Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial
Conference/Events	Celldex to host conference call » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 CLDX Celldex $36.70 / -0.665 (-1.78%) Conference call to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options CLDX Celldex $36.70 / -0.665 (-1.78%) 11/09/22 Celldex sees cash, equivalents sufficient to meet requirements through 2025 07/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab 06/30/22 Celldex presents positive Phase 1b interim data from barzolvolimab 06/21/22 Celldex announces first patient dosed in Phase 2 study of barzolvolimab CLDX Celldex $36.70 / -0.665 (-1.78%) 10/10/22 Jefferies Third Harmonic Bio initiated with a Buy at Jefferies 07/01/22 H.C. Wainwright Celldex price target raised to $73 from $60 at H.C. Wainwright CLDX Celldex $36.70 / -0.665 (-1.78%) 11/09/22 Celldex reports Q3 EPS (57c), consensus (58c) 08/08/22 Celldex reports Q2 EPS (77c) vs. (34c) last year CLDX Celldex $36.70 / -0.665 (-1.78%) 11/18/22 Sell these stocks now, proven algorithm says 09/16/22 Sell these stocks now, proven algorithm says 08:00 Today Celldex - CLDX CLDX Celldex $36.70 / -0.665 (-1.78%) 07/12/22 Celldex put volume heavy and directionally bearish
Conference/Events	Alphatec to participate in a conference call with Lake Street » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 ATEC Alphatec $9.75 / -0.525 (-5.11%) Key Opinion Leader… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events ATEC Alphatec $9.75 / -0.525 (-5.11%) 10/10/22 Alphatec reports preliminary Q3 revenue $89M-$90M, consensus $81.37M 07/14/22 Alphatec artificially inflated sales, Bonitas says in short report ATEC Alphatec $9.75 / -0.525 (-5.11%) 10/17/22 Lake Street Alphatec price target raised to $16.50 from $13 at Lake Street 10/12/22 Piper Sandler CMS proposal a positive for Med Tech sector, says Piper Sandler 10/12/22 Jefferies Alphatec initiated with a Buy at Jefferies 10/10/22 Piper Sandler Piper Sandler bullish on Alphatec following Q3 preliminary results ATEC Alphatec $9.75 / -0.525 (-5.11%) 11/03/22 Alphatec sees FY22 revenue $340M, consensus $328.2M 11/03/22 Alphatec reports Q3 EPS (35c), consensus (30c) 08/04/22 Alphatec raises FY22 revenue view to $325M, consensus $316.7M 08/04/22 Alphatec reports Q2 EPS (36c), consensus (29c) ATEC Alphatec $9.75 / -0.525 (-5.11%) 07/14/22 Bonitas Research reports short position in Alphatec ATEC Alphatec $9.75 / -0.525 (-5.11%) 10/10/22 What You Missed On Wall Street On Monday 10/10/22 What You Missed On Wall Street This Morning 07/14/22 What You Missed On Wall Street On Thursday 07/14/22 What You Missed On Wall Street This Morning 14:00 Today Alphatec - ATEC
Conference/Events	JPMorgan transportation/fuel analyst holds analyst/industry conference call » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 Transportation/Fuel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	BTIG medical technology analyst to hold a group dinner » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 Medical Tech &… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial

Conference/Events	BTIG policy director to hold an analyst/industry conference call » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 Policy Research Director… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	Janus International Group management to meet with KeyBanc » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 JBI Janus International Group $10.75 / -0.09 (-0.83%) Meetings to be held with… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events JBI Janus International Group $10.75 / -0.09 (-0.83%) 09/26/22 Janus International Group appoints Elliot Kahler as general counsel 06/21/22 Janus International Group appoints Anselm Wong as CFO, effective July 1 JBI Janus International Group $10.75 / -0.09 (-0.83%) 09/06/22 CJS Securities Janus International Group initiated with an Outperform at CJS Securities 01/26/22 Benchmark Janus International Group initiated with a Buy at Benchmark 12/08/21 Stifel Janus International Group initiated with a Buy at Stifel 12/07/21 UBS Janus International Group initiated with a Neutral at UBS JBI Janus International Group $10.75 / -0.09 (-0.83%) 11/10/22 Janus International Group ups FY22 revenue view to $990M-$1.01B from $940M-$960M 11/10/22 Janus International Group reports Q3 adjusted EPS 22c consensus 17c 08/16/22 Janus International Group reports Q2 EPS 17c, consensus 13c 06/21/22 Janus International Group backs FY22 revenue view $890M-$910M, consensus $908M JBI Janus International Group $10.75 / -0.09 (-0.83%) 06/21/22 What You Missed On Wall Street On Tuesday 06/21/22 What You Missed On Wall Street This Morning 00:00 Today Janus International Group 12/07/22 Janus International Group
Conference/Events	Comscore management to meet with Needham » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 SCOR Comscore $1.28 / -0.085 (-6.23%) Meetings to be held on… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events SCOR Comscore $1.28 / -0.085 (-6.23%) 11/22/22 Beneficial owner of Comscore Cerberus Capital buys 75,629 shares of stock 09/29/22 Comscore to reduce workforce, sees $13M-$18M in related costs 09/22/22 Comscore, dentsu partner transact on advanced audiences in local TV 08/29/22 Comscore director buys $731K in common stock SCOR Comscore $1.28 / -0.085 (-6.23%) 03/23/22 Craig-Hallum ComScore poised for share gains in local measurement, says Craig-Hallum 03/01/22 Truist Comscore price target lowered to $3.50 from $4 at Truist SCOR Comscore $1.28 / -0.085 (-6.23%) 11/08/22 Comscore cuts 2022 revenue growth estimate to low single digits 11/08/22 Comscore reports Q3 EPS (60c), consensus (10c) 08/09/22 Comscore sees FY22 revenue up 5%-7% over 2021, consensus $393.42M 08/09/22 Comscore reports Q2 EPS (10c) vs (28c) last year 00:00 Today Comscore 12/07/22 Comscore 12/08/22 Comscore 12/09/22 Comscore
Conference/Events	OmniAb to participate in a conference call with Benchmark » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 OABI OmniAb $3.91 / -0.06 (-1.51%) Healthcare Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events OABI OmniAb $3.91 / -0.06 (-1.51%) 12/01/22 Hillstream BioPharma announces development of Knob Quatrabodies OABI OmniAb $3.91 / -0.06 (-1.51%) 11/29/22 SVB Securities OmniAb initiated with an Outperform at SVB Securities 11/28/22 Stifel OmniAb initiated with a Buy at Stifel 10/25/22 H.C. Wainwright Ligand target lowered to $135 at H.C. Wainwright after OmniAb deal approved OABI OmniAb $3.91 / -0.06 (-1.51%) 11/04/22 Biotech Alert: Searches spiking for these stocks today 00:00 Today OmniAb - OABI
Conference/Events	Biogen and Sage Therapeutics to hold a joint investor webcast » 04:55 12/06/22 12/06 04:55 12/06/22 04:55 SAGE Sage Therapeutics $43.54 / -0.05 (-0.11%) , BIIB Biogen $292.64 / -6.35 (-2.12%) Biogen and Sage… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SAGE BIIB SAGE Sage Therapeutics $43.54 / -0.05 (-0.11%) 11/08/22 Sage sees cash and equivalents of $1.3B at end of FY22 11/01/22 Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer 10/17/22 Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression 09/19/22 Sage Therapeutics, Biogen present analyses on efficacy, safety of zuranolone BIIB Biogen $292.64 / -6.35 (-2.12%) 12/05/22 Biogen announces EMA accepted tofersen MAA to treat rare form of ALS 11/29/22 Eisai and Biogen present full results for Lecanemab phase 3 study in AD 11/10/22 Biogen names Viehbacher president, CEO 10/17/22 Biogen announces FDA's 3-month expansion of review filing for NDA for tofersen SAGE BIIB SAGE Sage Therapeutics $43.54 / -0.05 (-0.11%) 11/09/22 H.C. Wainwright Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright 11/01/22 Loop Capital Sage Therapeutics initiated with a Hold at Loop Capital 08/03/22 Citi Sage Therapeutics price target lowered to $40 from $41 at Citi 08/02/22 Stifel Sage Therapeutics price target lowered to $56 from $58 at Stifel BIIB Biogen $292.64 / -6.35 (-2.12%) 12/02/22 JonesTrading Anavex price target raised to $80 from $40 at JonesTrading 12/01/22 Atlantic Equities Biogen price target raised to $295 from $220 at Atlantic Equities 11/30/22 Mizuho Mizuho says Biogen not mentioned in 90 minute lecanemab presentation 11/30/22 Jefferies Biogen price target raised to $350 from $325 at Jefferies SAGE BIIB SAGE Sage Therapeutics $43.54 / -0.05 (-0.11%) 11/08/22 Sage Therapeutics reports Q3 EPS ($2.31), consensus ($2.21) 08/02/22 Sage Therapeutics reports Q2 EPS ($2.13), consensus ($2.15) BIIB Biogen $292.64 / -6.35 (-2.12%) 10/25/22 Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49 10/25/22 Biogen reports Q3 adjusted EPS $4.77, consensus $4.15 10/24/22 Notable companies reporting before tomorrow's open 10/24/22 Notable companies reporting before tomorrow's open BIIB BIIB Biogen $292.64 / -6.35 (-2.12%) 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 11/07/22 Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says 10/28/22 Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says 10/07/22 Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports BIIB BIIB Biogen $292.64 / -6.35 (-2.12%) 11/30/22 Fly Intel: Pre-market Movers 11/28/22 Fly Intel: Pre-market Movers 11/14/22 What You Missed On Wall Street On Monday 11/14/22 What You Missed On Wall Street This Morning 12/07/22 Biopharma Spotlight: Global Large Cap Virtual Conference 08:00 Today Biogen - BIIB 08:00 Today Sage Therapeutics - SAGE 12/15/22 Sage Therapeutics BIIB BIIB Biogen $292.64 / -6.35 (-2.12%) 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th

Events

Earnings calls, analyst events, roadshows and more

WDH
Today at 07:00

Waterdrop - WDH Conference Calls
CLDX
Today at 08:00

Celldex - CLDX Conference Calls
HEPS
Today at 08:00

Hepsiburada - HEPS Conference Calls
EDIT
Today at 08:00

Editas Medicine - EDIT Conference Calls
JILL
Today at 08:00

J.Jill - JILL Conference Calls
LILM
Today at 08:00

Lilium - LILM Conference Calls
BIIB
Today at 08:00

Biogen - BIIB Conference Calls
SAGE
Today at 08:00

Sage Therapeutics - SAGE Conference Calls
EGRX
Today at 08:00

Eagle Pharmaceuticals Firm Sponsored Meetings

Lotte New York Palace Hotel, New York, NY
SIG
Today at 08:30

Signet Jewelers - SIG Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	TOPS X TOPS TOP Ships Spot Secondary Managers: Maxim Priced at: $2.00 6.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Air Industries reports Q2 revenue $14M vs. $15.5M last year

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access